HDAC9 and cancer: It is hypothesized that upon entry into the reducing environment of a cancer cell, Cubisbel is activated by the reduction of Cu(II) to Cu(I), allowing for concomitant release of two equivalents of belinostat resulting in potent HDAC inhibition.